- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05841329
Efficacy of tDCS to Enhance Virtual Reality Exposure Therapy Response in Acrophobia
Efficacy of tDCS to Enhance Virtual Reality Exposure Therapy Response in Acrophobia: A Randomized Controlled Trial
The goal of this clinical trial is to examine whether transcranial direct current stimulation(tDCS) can enhance the effect of virtual reality exposure therapy(VRET) in acrophobia in college students with significant fear of heights. The main question it aims to answer are:
• the enhancement of tDCS on the effect of VRET Participants will randomly allocated to tDCS active stimulated group and sham stimulated group and receive VRET.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Shanghai Mental Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- the score of the AQ-Anxiety had to be at least 45.45(1SD below the mean of a previous acrophobia sample(Cohen, 1977));
- the participants had the avoidance behaviors in daily life and recognized the fear of height was excessive and unnecessary (the severity of fear of heights not less than 5 points at a scale from 0 to 10).
Exclusion Criteria:
- previous treatment for acrophobia, history or family history of any mental disorder (except for acrophobia), metal parts in the head, medical implants, increased intracranial pressure, pregnancy, current involvement in psycho- or pharmacotherapy, and cardiovascular or neurological diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: active group
receive active tDCS before VRET
|
High-definition tDCS (HD-tDCS, 4×1 montage, with 1 anode and 4 cathodes, (Soterix Medical, New York, NY, USA) was applied with battery-driven electrical stimulator (2001&4×1-C3A).
The center electrode was anode and placed over FPz (according to the EEG 10-20 system in order to target the medial prefrontal cortex).
The reference electrodes were cathodes and placed over AF7, AF8, F3, F4(see fig.
3).
Participants were randomized to receive 20 minutes of active(1.5mA)
or sham (0 mA) tDCS in a single-blind design.
In order to ensure that participants can gradually adapted to the current change, there was a 15-second current rising process before the stimulation and, a 15-second current falling process after the stimulation.
For sham tDCS, the device was automatically turned off after current reached 1.5 mA, thus providing 30s of ramping current stimulation, which made it difficult for participants to distinguish which kinds of stimulation they received.
The VRET was adapted on the basis of Öst's single exposure treatment paradigm and conducted by experienced psychotherapists following a standard exposure treatment manual..
An exposure therapy was divided into three parts: psychological education, exposure intervention and summary.
Each scene started with a 10-min psychological education followed up with the tDCS stimulation.
In exposure trail, participants ought to take an elevator to 100th, observe the environment and look down on the platform.
The psychotherapist guided participants to be exposed to the VR environment and helped them experience the process of anxiety decline in the exposure trail.
|
|
Sham Comparator: sham group
receive sham tDCS before VRET
|
The VRET was adapted on the basis of Öst's single exposure treatment paradigm and conducted by experienced psychotherapists following a standard exposure treatment manual..
An exposure therapy was divided into three parts: psychological education, exposure intervention and summary.
Each scene started with a 10-min psychological education followed up with the tDCS stimulation.
In exposure trail, participants ought to take an elevator to 100th, observe the environment and look down on the platform.
The psychotherapist guided participants to be exposed to the VR environment and helped them experience the process of anxiety decline in the exposure trail.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acrophobia Questionnaire(AQ)
Time Frame: one day(baseline, after invervention)
|
It consists of two scales that assess fear (Anxiety, ranging from 0 to 120, involving 20 height situations scored on a seven-point Likert scale; Cronbach' α = 0.80) and avoidance behaviors (Avoidance, ranging from 0 to 40, involving 20 height situations scored on a three-point Likert scale; Cronbach' α = 0.70) of height. Each scale contains 20 scenarios about height situation, such as "Standing next to an open window on the third floor". AQ is widely used to measure fear of heights and has good reliability. Change from Baseline AQ at post-intervention was assessed in the study. |
one day(baseline, after invervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heights Interpretation Questionnaire(HIQ)
Time Frame: one day(baseline, after invervention)
|
This scale is a 16-item self-report questionnaire that are rated on a 5-point Likert scale(1 to 5). It was designed to measure height-relevant interpretations. Total scores range from 16 to 80, with higher scores indicating more height-relevant interpretations. Change from Baseline HIQ at post-intervention was assessed in the study. |
one day(baseline, after invervention)
|
|
State-Trait Anxiety Inventory Form Y, (STAI-Y)
Time Frame: one day(baseline, after invervention)
|
This scale is a 40-item self-report questionnaire that are rated on a 4-point Likert scale(1 to 4). Higher scores indicate more state and trait anxiety. Change from Baseline STAI-Y at post-intervention was assessed in the study. |
one day(baseline, after invervention)
|
|
the Beck Anxiety Inventory(BAI)
Time Frame: one day(baseline, after invervention)
|
It is an inventory of anxiety symptoms with 18 items that are rated on a 5-point Likert scale(0 to 4). Total scores range from 0 to 72, with higher scores indicating more severe anxiety symptoms. Change from Baseline BAI at post-intervention was assessed in the study. |
one day(baseline, after invervention)
|
|
Subjective Units of Distress Scale(SUDS)
Time Frame: assessed every five minutes during intervention
|
This scale is used to assess the level of anxiety with 10 items that are rated from 0-10 point.
The higher score indicates more severe current anxiety or distress.
|
assessed every five minutes during intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SMHC-VR-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transcranial Direct Current Stimulation
-
Bar-Ilan University, IsraelRecruitingTranscranial Direct Current Stimulation | Transcranial Alternating Current StimulationIsrael
-
University Hospital, GrenobleUnknownHealthy | Transcranial Magnetic Stimulation | Transcranial Direct Current StimulationFrance
-
Beijing Sport UniversityNot yet recruitingTranscranial Direct Current Stimulation
-
NYU Langone HealthCompletedTranscranial Direct Current StimulationUnited States
-
Hebrew University of JerusalemCompletedTranscranial Direct Current StimulationIsrael
-
Arizona State UniversityNational Institute of Mental Health (NIMH)CompletedTranscranial Direct Current StimulationUnited States
-
United States Army Aeromedical Research LaboratoryCompletedTranscranial Direct Current StimulationUnited States
-
Beijing Sport UniversityNot yet recruitingTranscranial Direct Current Stimulation (tDCS)
-
University of MinnesotaNational Institute of Mental Health (NIMH)CompletedMaximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 1 (MINUTES)Healthy | Transcranial Direct Current StimulationUnited States
-
Johns Hopkins UniversityNational Institute on Aging (NIA)Active, not recruitingTranscranial Direct Current Stimulation
Clinical Trials on tDCS
-
Hôpital le VinatierCompletedSchizophrenia | Auditory HallucinationsFrance, Tunisia
-
Northeastern UniversityMassachusetts General Hospital; National Institute on Aging (NIA)Unknown
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de...Enrolling by invitationSubstance-Related DisordersSpain
-
Thorsten RudroffTerminatedMultiple Sclerosis | Neuropathic PainUnited States
-
Bambino Gesù Hospital and Research InstituteCompleted
-
Nachum Soroker, MDUnknown
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedMotor Activity | Motor NeuroplasticityUnited States
-
Charite University, Berlin, GermanyCompletedMigraine With Aura | CADASIL | Cerebral Microangiopathy | ICA StenosisGermany
-
University of MichiganNational Institute of Mental Health (NIMH)Completed
-
New York UniversityRecruiting